Clinical acceleration of JAK2 p.V617F driven myeloproliferative disease due to an uncommon homozygous MPL p.Y591D mutation.

Clinical acceleration of JAK2 p.V617F driven myeloproliferative disease due to an uncommon homozygous MPL p.Y591D mutation. Haematologica. 2020 Jun 04;: Authors: Ong J, Lin JI, Mitchell H, Morgan S, Perkins AC PMID: 32499240 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32499240?dopt=Abstract

Source: Haematologica - June 3, 2020 Category: Hematology Authors: Ong J, Lin JI, Mitchell H, Morgan S, Perkins AC Tags: Haematologica Source Type: research

More News: Hematology | Myeloproliferative Disorders